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Due to its prevalence, prostate cancer represents a serious health problem. The treatment, when required, may be local in case of
limited disease, locoregional if lymph nodes are involved, and systemic when distant metastases are present. In order to choose the
best treatment regimen, an accurate disease staging is mandatory. However, the accuracy of conventional imaging modalities in
detecting lymph node and bone metastases is low. In the last decade, molecular imaging, particularly, choline PET-CT has been
evaluated in this setting. Choline PET represents the more accurate exam to stage high-risk prostate cancer, and it is useful in
staging patients with biochemical relapse, in particular when PSA kinetics is high and/or PSA levels are more than 2pg/ml. The
present paper reports results of available papers on these issues, with particular attention to lymph node staging.
1.Introduction
Due to its prevalence, prostate cancer represents a medical
and social problem [1]. In developed countries, among the
male cancer, it is the most common one and the second
c a u s eo fc a n c e rd e a t hi nm e no v e r5 0y e a r s[ 2, 3]. Thanks
to the Prostate Speciﬁc Antigen (PSA) screening, in most
of the cases, the disease extension at diagnosis is limited.
Despite, the relapse is quite common [4], and due to this
reason, a strict monitoring of the PSA levels is generally
performed [5]. Increases of PSA are the expression of disease
relapse, while PSA velocity [3] or PSA doubling time [6]
shows a good correlation with the amount of the disease. In
presence of relapse, an accurate disease staging is mandatory
due to the fact that local and distant relapse present diﬀerent
prognosis and therapeutic approaches. In case of localized
or locoregional disease, the salvage radical prostatectomy is
indicated (eventually lymphadenectomy), whereas in case of
distant metastases, androgen deprivation therapy (ADT) or
surveillance is recommended (localized radiotherapy can be
of help in those cases with painful bone metastases [4, 7]).
Forseveraldecades,thecontributionofnuclearmedicine
in prostate cancer has been limited to the bone scan, in
order to detect bone metastases [8, 9] and to the prostascint
(capromab pendetide, a murine monoclonal antibody) in
order to detect and potentially treat primary prostate cancer
[8]. In the last two decades, PET scan became available and
was used in these patients. However, 18F-FDG (the most
extensively used tracer in PET imaging) has low sensitivity
in identifying prostate cancer, and its physiological urinary
excretion reduces speciﬁcity in the staging of locoregional
disease [8]. Acetate has been studied by few authors in
cases of biologic relapse of prostate cancer [8]b u te v e ni f
results seem to be interesting, the little number of studied
patients does not let as draw any deﬁnitive conclusions.
Thanks to its elevated values of sensitivity and speciﬁcity,
nowadays, the most extensively tracer used in patients with
prostate cancer is choline labeled with 11C or 18F. Hara and
DeGrado independently developed chemical ways to label
choline, initially with 11C [10, 11] and ﬁnally with 18F [12].
Another relevant step was represented by the introduction
of PET/CT scanners because of the signiﬁcant increase on
sensitivity and speciﬁcity in disease detection compared to
PET alone [13]. PET/CT choline shows great potential in
the staging of prostate cancer, and interesting results have
been published; the aim of this paper is to summarize the2 ISRN Oncology
results of studies evaluating the accuracy of choline PET/CT
in the lymph nodal staging of patients with prostate cancer.
We reviewed the literature with the help of the Medline
search engine PubMed. The search was performed using
keywords such as “choline PET” and “prostate cancer” and
was limited to works published in English, with particular
attention on lymph node staging. Furthermore, manual
searchesofreferenceslistedintheincludedpaperscompleted
our literature search.
2.Why Is Choline Interesting?
In order to facilitate their duplication, prostate cells accumu-
latecholine thatis usefulfortheproductionofphosphatidyl-
choline,acellmembraneconstituent.Thisabilityismoresig-
niﬁcant in prostate cancer cells [10]. Therefore, in 1998 Hara
et al. [10] evaluated 11C-choline PET in few patients with
prostate cancer and compared results with 18F-FDG PET.
11C-choline PET showed higher tumour/background ratio
with respect to 18F-FDG and false-positive rate was lower.
In 2002, the same group developed the synthesis of 18F-
ﬂuoroethylcholine, with longer half-life than 11C-choline
(120versus20minutes).Thisnewtracermaintainstheprop-
ertiesofthepreviousone,butitcanbeusedevenbyPETcen-
terswithouton-sitecyclotron[14].Sincethen,severalstudies
evaluating these tracers have been published. Hara and
DeGrado showed that prostate cancer cells uptake preference
was choline > acetate > FDG in aerobic conditions [15].
The group of DeGrado showed that these preferences were
valid both in androgen-dependent and -independent cells
[16]. The group of Groningen produced another 18F-labeled
choline compound (i.e., deshydroxy-ﬂuorocholine) in order
to diﬀerentiate between the choline kinase activity into the
cell and the choline transport from the intercellular space to
the cell [17], and another 18F-labeled compound has been
synthesized in order to further increase tumour/background
ratio[11]. Choline has been evaluated with success in animal
studies in order to predict early response to new cancer
treatments [18, 19], and thanks to the animal PET studies,
the basic research in this ﬁeld is very active.
Speaking about cancer diagnosis, the group of Bologna
evaluated the accuracy of 11C-choline PET in identifying
tumours foci in the prostate compared with sextant biopsy.
Positive predictive value was interesting but false-negative
rates were too high [20]. However, when evaluating only
nodules greater than 5mm, the sensitivity was good (83%)
[21]. The authors described similar speciﬁcities between
choline PET/CT and MRI spectroscopy [22]. The group
of Ulm showed that 11C-choline PET/CT detected and
correctly located major areas of prostate cancer with an AUC
(area under curve) of 0.89 ± 0.01 for a Standardized Uptake
Value (SUV) threshold of 2.65 [23, 24]. However, they
underlined that choline PET/CT was not accurate in order
to perform a nerve sparing radical prostatectomy due to the
low spatial resolution [25]. The group of Hawaii detected
prostate cancer with a high degree of conﬁdence (AUC =
0.93) using dynamic 18F choline PET [26, 27], in particular
using the (delayed-early) SUVmax. Other authors observed
that SUVmax was not able to distinguish with a high degree
of conﬁdence between prostate cancer and benign prostate
hyperplasia (BPH); in this case, the ratio between SUVmax
of prostate cancer and that of pelvic muscle can be useful
[28]. The group of Zurich published discouraging results
in staging prostate cancer with choline PET/CT, while they
showed its usefulness in the staging of patients with radical
prostatectomy and PSA levels >2ng/mL[29].
Picchio and coworkers, from Milan, compared 11C-
choline with FDG for restaging prostate cancer [30]. They
showed the superiority of choline in respect to conventional
imaging and promoted the integration of PET to the
conventional diagnostic workup. In another study, they
showed that choline could be useful to monitor the response
to the antiandrogenic therapy [31]. Evaluating the role
of 11C-choline in patients with biochemical relapse, the
group of Bologna pointed out that PSA levels (best cutoﬀ
2.43ng/mL) and PSA kinetics (velocity and/or doubling
time) are correlated with the detection rate [32]. Moreover,
whenusedtostagepatientswithsingleequivocalbonelesion,
PET choline frequently detected further lesions, leading to
the modiﬁcation of the treatment choice [33]. Interestingly,
in the restaging of patients with or without biochemical
progression, the group of Ulm showed a good accuracy of
choline PET (37 out of 49 patients were correctly classiﬁed,
accuracy: 75.6%) [34]. On the other hand, our group,
studied 56 patients with biochemical relapse and found an
increase of 18F-choline sensitivity with the increment of PSA
levels. We were able to detect recurrences in 24 patients: 4
local recurrences and 20 regional and/or systemic diseases
[1].
Other groups studied the role of choline PET/CT in
the detection of bone metastases [35, 36] and showed that
choline was able to distinguish between viable and sclerotic
lesions that present the same aspect on CT scan. Few
works evaluated the role of choline PET in radiotreatment
planning with promising results [37–39]. Finally, it seems
that choline PET could fulﬁll RECIST criteria to measure
tumour response [40].
Concluding, given the spatial resolution of PET systems
(about 5mm), choline PET could be useful to detect lesions
greater than 5mm within prostate gland, especially when the
acquisition is dynamic, or when early and delayed images
are both acquired (dual phase). In patients radically treated,
PSA remains the ﬁrst step in the followup, and only on its
basis choline PET can be required. In case of bone metastases
choline PET is useful due to its ability to distinguish between
viable and sclerotic lesions. Furthermore, choline PET is
more sensitive than bone scintigraphy. Finally, PET abilities
can be exploited to optimize radiotherapy plan and to
evaluate treatment response according to RECIST criteria.
3. Choline PETinLymph Node Staging?
The prostate lymphatics drain into the obturator/internal
iliac, external iliac, presacral/perirectal nodes, and, less
frequently, into the common iliac nodes [41]. Morphological
imaging shows very low sensitivity in this setting [1, 41];
functional/molecular imaging, and so choline PET/CT has
been widely investigated in order to deﬁne its accuracy.ISRN Oncology 3
4. Lymph Node Stagingin
ProstateCancer
Recently, the group of Linz presented the results of a
prospective study with histopathologic conﬁrmation on 130
intermediate and high-risk patients with newly diagnosed
prostatecancerstudiedwithcholinePET[42].Theyreported
a per lesion sensitivity of 45% that grows to 66% for lymph
node greater than 5mm; speciﬁcity was 96%. By acquiring
delayed images, they observed an early wash out of choline
in false positive lymph nodes. So the authors concluded that
PET is an useful tool to stage patients, especially those with
high-risk prostate cancer. The groups of Milan and Bologna
studied together the accuracy on lymph node staging of 57
patients with prostate cancer and compared it with clinical
nomograms. PET sensitivity, speciﬁcity, positive predictive
value (PPV), negative predictive value (NPV), and accuracy
in the patient-based analysis were 60%, 98%, 90%, 87%,
and 87%, while in the lesion-based analysis were 41%,
99.8%, 94%, 97%, and 97%, respectively. The speciﬁcity
of PET scan was better than the speciﬁcity of clinical
nomogram; the sensitivity was similar, and even in this
study results inﬂuenced by the diameter of the lesions [43].
AD a n i s hs t u d y[ 44] prospectively evaluated the accuracy
of 18F-choline PET/CT in the detection of lymph node
metastases in 25 patients with newly diagnosed intermediate
or high-risk prostate cancer. The results were compared
with histopathology after lymphadenectomy. PET/CT was
positive in four, and three among them were true positive.
The authors did not ﬁnd false-negative results nor observe
signiﬁcant diﬀerences between SUVmax in the early and
in the late images. They concluded that choline PET was
promising, but due to the reduced number of patients,
further studies are necessary. Another study reported an
accuracy of 93% in the lymph node staging of 67 patients
with newly diagnosed prostate cancer [45]. In this latter,
choline PET was highly speciﬁc (96%) and presented a
good sensitivity (80%). On the other hand, discouraging
results have been reported by other authors. Steuber et al.
[46] evaluated prospectively 18F ﬂuoroethylcholine PET/CT
in 20 high-risk patients with prostate cancer prior to
the radical prostatectomy and compared PET results with
histopathology. They did not observe pathological uptake
at PET scan while on histopathology, 31 metastatic lymph
n o d e sw e r eo b s e r v e d .H ¨ acker et al. [47] staged 20 patients
with intermediate or high-risk prostate cancer. In 10 cases
at least one metastatic lymph node was observed, and 18F-
choline PET/CT showed a sensitivity of 10%, a speciﬁcity
of 80%, and an accuracy of 45%. Budiharto et al. [48],
recently, staged 36 patients by the use of 11C-choline PET
and compared the results with histopathology. This group
found a sensitivity of PET scan under 10% on a per lesion
basis and a speciﬁcity of 99.7%. Another similar work was
performed by Scher et al. [49] that studied 58 patients
with the clinical suspicion of prostate cancer. Authors found
lymph node metastases in 5 of these cases, and PET scan
missed one with micrometastases. The limit of this study
is that histopathologic conﬁrmation was available only for
positive PET exams and not for the negative ones.
5. Lymph Node Detectionin
ProstateCancer Relapse
The group of Milan studied 358 patients, and 161 of them
showed at least one abnormal choline uptake [2]. Lymph
nodespathologicaluptakewasobservedin107bothinpelvic
area (more frequently), and in retroperitoneal area (less
frequently) and no signiﬁcant diﬀerences were observed in
the accuracy of this exam in patients with ADT compared
with those without, whereas the increase of PSA levels
correlated with sensitivity in the detection of lymph node
metastases. In another study, the same group evidenced an
overall PET accuracy of 77% on a per-lesion basis, with
sensitivity, speciﬁcity, PPV, and NPV of 64%, 90%, 86%, and
72%, respectively (the low NPV was attributed to the limited
spatial resolution of the tomograph). Finally in a subsequent
study [6], the authors observed that PSA doubling time
shorter than 6 months was independently correlated with
greaterpercentageofpatientswithpathologicallymphnodes
uptakes. The group of Bologna studied 102 patients in
the same setting and found 12 lymph nodes pathological
uptakes in 9 patients, all true positive [3]. In this study,
the PSA doubling time independently predicted choline
PET positivity. Recently, a Dutch group evaluated choline
PET in restaging 70 patients with biochemical relapse. They
observed pathological uptake in 10 lymph nodes, and among
them, only one was false positive [50]. The group of Munich
[51]usedcholinePET/CTtostudypatientswithbiochemical
relapse of prostate cancer. Thirty-ﬁve of 63 patients showed
pathological uptakes in choline PET/CT, and among them,
15 demonstrated focal uptake in abdominopelvic lymph
nodes. Furthermore, this group compared low-dose CT with
diagnostic CT scan, concluding that this latter increased sen-
sitivity and speciﬁcity of the PET exam [7]. Rinnab et al. [52]
studied 50 patients with biochemical relapse and observed
lymph node uptake in 13 of them, however histopathology
conﬁrmed only 9 metastases with a predictive positive value
of 69% (9/13). Even in this study, the increment of PSA level
was related with an increment of PET sensitivity. Schilling
et al. [53] studied the positive predictive value of choline
PET/CT in 10 patients with biochemical failure and positive
lymph nodes at 11C-choline PET scan. Histopathologic
results showed metastatic disease in 7 of them (PPV of
70%), and PSA was signiﬁcantly greater in that group with
respect to the group of false positives. Finally, Cimitan et al.
[54],using18Fcholine,staged100patientswithbiochemical
relapse. They found pathological uptake in 54 cases, and in
16 of them, metastatic lymph nodes were observed. Even in
this study, choline PET increased its sensitivity in the group
of patients with PSA greater than 4ng/mL.
6. Conclusion
Todate,therearenoconcordantresultsontheroleofcholine
PET in lymph node staging of patients with new diagnosis
of prostate cancer. The low PET spatial resolution could be,
the most relevant limit. However, it should be pointed out
thatinthissetting,otherimagingmodalitiesarelessaccurate,
and so PET represents the best non invasive choice [42, 43].4 ISRN Oncology
Taking into consideration the utility in the early detection of
bone metastases, we think that choline PET could have a role
in this setting, in particular in high-risk patients. Finally, the
evaluationof novel treatments has potential advantages from
the use of choline PET.
The other setting in which choline PET can have a
strategic role is in the staging of patients with biochemical
relapse. In this ﬁeld, the majority of the studies missed
an extended histopathology conﬁrmation, and the only
value most frequently considered is the PPV. The added
value of choline PET could be observed by restaging these
patients, in particular those with greater PSA values and
higher PSA kinetics. Anyway, well-structured studies with
histopathology conﬁrmation may be useful to determine the
real accuracy of this exam.
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